Consequently, future pharmacological efforts must focus on deciphering these intricate downstream pathways to successfully harness the receptor\u2019s broad therapeutic potential and translate GPR120 vast biological promise into effective clinical treatments.<\/p>\n\n\n\n
Lessons from developing the GPR120 platform<\/strong><\/h3>\n\n\n\n\n- Target biology should dictate <\/a>assay design<\/a>.<\/li>\n\n\n\n
- Functional readouts provide greater biological relevance than expression alone.<\/li>\n\n\n\n
- Stable clone selection is critical for minimizing assay variability.<\/li>\n\n\n\n
- Reproducibility is essential before progressing to large-scale screening.<\/li>\n\n\n\n
- Early investment in assay quality reduces downstream screening risk.<\/li>\n<\/ul>\n\n\n\n
What Is GPR120?<\/strong><\/strong><\/h2>\n\n\n\nGPR120 is a Class A G protein-coupled receptor (GPCR)<\/a> that is activated by medium-to-long-chain free fatty acids, particularly omega-3 fatty acids such as \u03b1-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Activation of the receptor has been linked to the regulation of lipid and energy metabolism, glucose homeostasis by promoting insulin sensitization, and ameliorating inflammation, positioning GPR120 at the intersection of several pathways implicated in metabolic disease.<\/p>\n\n\n\nGPR120 exhibits remarkably broad tissue distribution that underlies its pleiotropic physiological roles and expands therapeutic opportunities across multiple disease indications. The highest expression levels are observed in intestinal enteroendocrine L-cells and K-cells (incretin hormone release and appetite regulation), pancreatic islets (enhancement of glucose-stimulated insulin secretion and somatostatin release), adipose tissue (regulation of adipogenesis, lipolysis, thermogenesis, and adipokine secretion), macrophages and microglia (mediation of anti-inflammatory polarization and phagocytic function), central nervous system (energy balance and neurodegeneration) (Figure 1).<\/p>\n\n\n\n![\"Bar](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-1-Tissue-Expression.webp\")
Figure 1<\/strong>. Tissue expression profile of GPR120 (FFAR4) across metabolically relevant tissues. The dataset consists of normalized expression (nTPM, which stands for normalized Transcripts Per Million) levels for 55 tissue types, created by combining the HPA and GTEx transcriptomics datasets. Color-coding is based on tissue groups, each consisting of tissues with functional features in common. Detailed data available here<\/a>.<\/figcaption><\/figure>\n\n\n\nThis distribution is consistent with the receptor\u2019s emerging role as a regulator of multiple physiological processes, including glucose homeostasis, lipid metabolism, hormone secretion, inflammatory signalling and neurodegeneration.<\/p>\n\n\n\n
The Complexity of GPR120 Signaling<\/strong><\/h2>\n\n\n\nOne reason GPR120 has generated significant scientific interest is its complex signaling biology. Rather than acting within a single metabolic pathway, GPR120 appears to function as part of a wider network that integrates nutritional status with downstream cellular responses. This has made it an attractive target for researchers investigating obesity, type 2 diabetes, and steatotic liver diseases, where dysregulation occurs across multiple interconnected systems.<\/p>\n\n\n\n
In humans, two gene products arise upon alternative splicing of exon 3, that can form longer form of GPR120, commonly referred to as FFA4-\u2019Long\u2019 (FFA4-L), as well as a shorter transcript, referred to as FFA4-\u2019Short\u2019 (FFA4-S). FFA4-L contains an additional 16 amino acid sequence within intracellular loop 3 (ICL3), a GPCR domain typically involved in protein interactions, downstream signaling, and desensitization.<\/p>\n\n\n\n
The receptor is known to signal through both G\u03b1q\/11<\/sub>-mediated pathways and \u03b2-arrestin 2 recruitment pathways, each contributing to different downstream cellular responses. These pathways influence a range of biological outcomes, including hormone secretion, glucose uptake, cell survival, and inflammatory regulation.<\/p>\n\n\n\n![\"Schematic](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/2026_09_GPR120_Schematic.webp\")
Figure 2<\/strong>. Major signaling pathways used by GPR120. On the left panel, the G protein-mediated activation via G\u03b1q\/11 leads to the activation the activation of the enzyme phospholipase \u03b2 (PLC \u03b2). This produces inositol-3-phosphate (IP3) as a second messenger, resulting in the release of intracellular calcium, with important biological effects such as gut hormones secretion and glucose homeostasis. On the right panel, the \u03b2-arrestin-2 recruitment upon agonist-mediated activation of GPR120 leads to the beginning of anti-inflammatory signaling, involved in the lipid metabolism and inflammatory response modulation.<\/figcaption><\/figure>\n\n\n\nFollowing identification of different isoforms, it was reported that in response to agonism with the long-chain unsaturated fatty acid oleic acid, native FFA4-L is indeed unable to elicit Ca2+ responses, while FFA4-S produced robust Ca2+ mobilization, suggesting that the short variant of the receptor couples to Ca2+ signaling via G\u03b1q\/11<\/sub>. Both FFA4-L and FFA4-S elicited similar responses toward recruitment of \u03b2-arrestin2, and subsequently, both demonstrate robust internalization and are targeted to lysosomal compartments for degradation. This highlights the signaling differences between the two transcript variants and suggests that the insertion of the 16 amino acids into ICL3 of FFA4-L facilitates intrinsic bias toward \u03b2-arrestin signaling.<\/p>\n\n\n\nScientists studying GPR120 are therefore faced with an important challenge:<\/p>\n\n\n\n
Which signaling pathway should be prioritized when evaluating potential drug candidates?<\/strong><\/h4>\n\n\n\nThe answer depends on the therapeutic objective. Understanding the biological relevance of each signaling route is essential when selecting assay formats and designing screening strategies, especially for a complex target like GPR120.<\/p>\n\n\n\n
Why Functional Assays Matter<\/strong><\/h2>\n\n\n\nIn GPCR drug discovery, measuring receptor activation is only part of the challenge. Equally important is ensuring that the chosen assay reflects the biology most relevant to the disease being studied. Poor target validation<\/a> remains a significant contributor to late-stage attrition in drug development. At Sygnature Discovery, we view the whole discovery pipeline as one integrated feedback loop in order to de-risk progression. Therefore, we use our experience and expertise to ensure that target validation is carried out to the highest accuracy using in-house functional assay development<\/a> to study our targets.<\/p>\n\n\n\nFor GPR120, the G\u03b1q\/11<\/sub> signaling pathway plays an important role in mediating metabolic effects. As a result, calcium mobilization provides a practical and biologically relevant functional readout for screening programs focused on metabolic applications.<\/p>\n\n\n\nFluorescence-based calcium flux assays offer several advantages:<\/p>\n\n\n\n
\n- Real-time measurement of receptor activation<\/li>\n\n\n\n
- Quantitative assessment of ligand potency<\/li>\n\n\n\n
- Compatibility with high-throughput screening workflows<\/li>\n\n\n\n
- Direct interrogation of G\u03b1q\/11<\/sub>-mediated signaling pathways<\/li>\n<\/ul>\n\n\n\n
As interest in GPR120 grows, robust functional assays will be increasingly important for identifying and characterizing novel agonists, antagonists, and allosteric modulators.<\/p>\n\n\n\n
Building a Screening-Ready GPR120 Platform<\/strong><\/h2>\n\n\n\nTo ensure that screening platforms yield predictive, high-confidence results, target biology must dictate assay design from the ground up. At Sygnature Discovery, building a screening-ready GPR120 platform reflects this philosophy, progressing systematically from construct validation and stable clone selection to rigorous pharmacological characterization.<\/p>\n\n\n\n
Indeed, to achieve a reliable screening assay, the full process begins with construct validation via (q)PCR or Western Blot to assess that the target is correctly expressed in cells and it is detectable, followed by the generation and evaluation of stable cell lines capable of delivering strong signal windows, low background activity, and reproducible pharmacological responses.<\/p>\n\n\n\n
In Sygnature Discovery\u2019s internally developed GPR120 platform, initial validation was performed using transiently transfected HEK 293 cells, demonstrating functional responses to the selective GPR120 agonist TUG-891(Figure 3).<\/p>\n\n\n\n
\n<\/div>\n\n\n\n\n![\"Concentration-response](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-3-Dose-dependent-activation-of-GPR120-1.webp\")
Figure 3.<\/strong> Validation of TUG-891 in HEK inducible cells transiently expressing GPR120. Upon induction with tetracycline to express GPR120 in transiently transfected HEK inducible cells, a calcium assay was carried out to validate the functionality of the plasmid coding for GPR120 in presence of the agonist TUG-891. As a comparison, cells transfected with an empty vector did not show any response, indicating the specificity of the activation generated after agonist addition.<\/figcaption><\/figure>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\nStable transfectants were then generated and screened to identify clones capable of supporting robust calcium flux measurements. Several single cell-derived clones expressing GPR120 were evaluated to select those with the strongest assay performance (Figure 4). Once the best clone has been selected, assay optimization and further studies are carried out to pharmacologically characterize the selected clones, and a further stock generation of the selected clones is carried out. This ensures homogeneous receptor expression across stocks and their long-term availability.<\/p>\n\n\n\n![\"Four](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Screenshot-2026-11-05-163438.webp\")
Figure 4.<\/strong> Clone screening of GPR120 clone in HEK inducible stable cell line. The four panels show differences in response across single cell-derived clones in calcium assay via FLIPR. Data is presented as fold over the vehicle.<\/figcaption><\/figure>\n\n\n\nAfter selecting the best clone, this was subsequently characterized using both the selective agonist TUG-891 and the reference antagonist AH7614 to confirm pharmacological responsiveness and receptor-specific activity (Figure 5). The tests were carried out in different independent experiments to determine the assay reproducibility, as well as the consistency in GPR120 expression across passages of the same cell line (Figure 6).<\/p>\n\n\n\n![\"Two](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-5-Characterization-of-GPR120.webp\")
Figure 5<\/strong>. Characterization of GPR120 using a calcium flux assay via FLIPR. Agonist concentration-response curve (top panel) shows a concentration-dependent activation of GPR120 in presence of increasing concentrations of TUG-891. In the bottom panel, a concentration-response curve is displayed for AH 7614 antagonist, showing that increasing concentrations of antagonist block GPR120 activation.<\/figcaption><\/figure>\n\n\n\n
What Is GPR120?<\/strong><\/strong><\/h2>\n\n\n\nGPR120 is a Class A G protein-coupled receptor (GPCR)<\/a> that is activated by medium-to-long-chain free fatty acids, particularly omega-3 fatty acids such as \u03b1-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Activation of the receptor has been linked to the regulation of lipid and energy metabolism, glucose homeostasis by promoting insulin sensitization, and ameliorating inflammation, positioning GPR120 at the intersection of several pathways implicated in metabolic disease.<\/p>\n\n\n\nGPR120 exhibits remarkably broad tissue distribution that underlies its pleiotropic physiological roles and expands therapeutic opportunities across multiple disease indications. The highest expression levels are observed in intestinal enteroendocrine L-cells and K-cells (incretin hormone release and appetite regulation), pancreatic islets (enhancement of glucose-stimulated insulin secretion and somatostatin release), adipose tissue (regulation of adipogenesis, lipolysis, thermogenesis, and adipokine secretion), macrophages and microglia (mediation of anti-inflammatory polarization and phagocytic function), central nervous system (energy balance and neurodegeneration) (Figure 1).<\/p>\n\n\n\nFigure 1<\/strong>. Tissue expression profile of GPR120 (FFAR4) across metabolically relevant tissues. The dataset consists of normalized expression (nTPM, which stands for normalized Transcripts Per Million) levels for 55 tissue types, created by combining the HPA and GTEx transcriptomics datasets. Color-coding is based on tissue groups, each consisting of tissues with functional features in common. Detailed data available here<\/a>.<\/figcaption><\/figure>\n\n\n\nThis distribution is consistent with the receptor\u2019s emerging role as a regulator of multiple physiological processes, including glucose homeostasis, lipid metabolism, hormone secretion, inflammatory signalling and neurodegeneration.<\/p>\n\n\n\n
The Complexity of GPR120 Signaling<\/strong><\/h2>\n\n\n\nOne reason GPR120 has generated significant scientific interest is its complex signaling biology. Rather than acting within a single metabolic pathway, GPR120 appears to function as part of a wider network that integrates nutritional status with downstream cellular responses. This has made it an attractive target for researchers investigating obesity, type 2 diabetes, and steatotic liver diseases, where dysregulation occurs across multiple interconnected systems.<\/p>\n\n\n\n
In humans, two gene products arise upon alternative splicing of exon 3, that can form longer form of GPR120, commonly referred to as FFA4-\u2019Long\u2019 (FFA4-L), as well as a shorter transcript, referred to as FFA4-\u2019Short\u2019 (FFA4-S). FFA4-L contains an additional 16 amino acid sequence within intracellular loop 3 (ICL3), a GPCR domain typically involved in protein interactions, downstream signaling, and desensitization.<\/p>\n\n\n\n
The receptor is known to signal through both G\u03b1q\/11<\/sub>-mediated pathways and \u03b2-arrestin 2 recruitment pathways, each contributing to different downstream cellular responses. These pathways influence a range of biological outcomes, including hormone secretion, glucose uptake, cell survival, and inflammatory regulation.<\/p>\n\n\n\nFigure 2<\/strong>. Major signaling pathways used by GPR120. On the left panel, the G protein-mediated activation via G\u03b1q\/11 leads to the activation the activation of the enzyme phospholipase \u03b2 (PLC \u03b2). This produces inositol-3-phosphate (IP3) as a second messenger, resulting in the release of intracellular calcium, with important biological effects such as gut hormones secretion and glucose homeostasis. On the right panel, the \u03b2-arrestin-2 recruitment upon agonist-mediated activation of GPR120 leads to the beginning of anti-inflammatory signaling, involved in the lipid metabolism and inflammatory response modulation.<\/figcaption><\/figure>\n\n\n\nFollowing identification of different isoforms, it was reported that in response to agonism with the long-chain unsaturated fatty acid oleic acid, native FFA4-L is indeed unable to elicit Ca2+ responses, while FFA4-S produced robust Ca2+ mobilization, suggesting that the short variant of the receptor couples to Ca2+ signaling via G\u03b1q\/11<\/sub>. Both FFA4-L and FFA4-S elicited similar responses toward recruitment of \u03b2-arrestin2, and subsequently, both demonstrate robust internalization and are targeted to lysosomal compartments for degradation. This highlights the signaling differences between the two transcript variants and suggests that the insertion of the 16 amino acids into ICL3 of FFA4-L facilitates intrinsic bias toward \u03b2-arrestin signaling.<\/p>\n\n\n\nScientists studying GPR120 are therefore faced with an important challenge:<\/p>\n\n\n\n
Which signaling pathway should be prioritized when evaluating potential drug candidates?<\/strong><\/h4>\n\n\n\nThe answer depends on the therapeutic objective. Understanding the biological relevance of each signaling route is essential when selecting assay formats and designing screening strategies, especially for a complex target like GPR120.<\/p>\n\n\n\n
Why Functional Assays Matter<\/strong><\/h2>\n\n\n\nIn GPCR drug discovery, measuring receptor activation is only part of the challenge. Equally important is ensuring that the chosen assay reflects the biology most relevant to the disease being studied. Poor target validation<\/a> remains a significant contributor to late-stage attrition in drug development. At Sygnature Discovery, we view the whole discovery pipeline as one integrated feedback loop in order to de-risk progression. Therefore, we use our experience and expertise to ensure that target validation is carried out to the highest accuracy using in-house functional assay development<\/a> to study our targets.<\/p>\n\n\n\nFor GPR120, the G\u03b1q\/11<\/sub> signaling pathway plays an important role in mediating metabolic effects. As a result, calcium mobilization provides a practical and biologically relevant functional readout for screening programs focused on metabolic applications.<\/p>\n\n\n\nFluorescence-based calcium flux assays offer several advantages:<\/p>\n\n\n\n
\n- Real-time measurement of receptor activation<\/li>\n\n\n\n
- Quantitative assessment of ligand potency<\/li>\n\n\n\n
- Compatibility with high-throughput screening workflows<\/li>\n\n\n\n
- Direct interrogation of G\u03b1q\/11<\/sub>-mediated signaling pathways<\/li>\n<\/ul>\n\n\n\n
As interest in GPR120 grows, robust functional assays will be increasingly important for identifying and characterizing novel agonists, antagonists, and allosteric modulators.<\/p>\n\n\n\n
Building a Screening-Ready GPR120 Platform<\/strong><\/h2>\n\n\n\nTo ensure that screening platforms yield predictive, high-confidence results, target biology must dictate assay design from the ground up. At Sygnature Discovery, building a screening-ready GPR120 platform reflects this philosophy, progressing systematically from construct validation and stable clone selection to rigorous pharmacological characterization.<\/p>\n\n\n\n
Indeed, to achieve a reliable screening assay, the full process begins with construct validation via (q)PCR or Western Blot to assess that the target is correctly expressed in cells and it is detectable, followed by the generation and evaluation of stable cell lines capable of delivering strong signal windows, low background activity, and reproducible pharmacological responses.<\/p>\n\n\n\n
In Sygnature Discovery\u2019s internally developed GPR120 platform, initial validation was performed using transiently transfected HEK 293 cells, demonstrating functional responses to the selective GPR120 agonist TUG-891(Figure 3).<\/p>\n\n\n\n
\n<\/div>\n\n\n\n\nFigure 3.<\/strong> Validation of TUG-891 in HEK inducible cells transiently expressing GPR120. Upon induction with tetracycline to express GPR120 in transiently transfected HEK inducible cells, a calcium assay was carried out to validate the functionality of the plasmid coding for GPR120 in presence of the agonist TUG-891. As a comparison, cells transfected with an empty vector did not show any response, indicating the specificity of the activation generated after agonist addition.<\/figcaption><\/figure>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\nStable transfectants were then generated and screened to identify clones capable of supporting robust calcium flux measurements. Several single cell-derived clones expressing GPR120 were evaluated to select those with the strongest assay performance (Figure 4). Once the best clone has been selected, assay optimization and further studies are carried out to pharmacologically characterize the selected clones, and a further stock generation of the selected clones is carried out. This ensures homogeneous receptor expression across stocks and their long-term availability.<\/p>\n\n\n\nFigure 4.<\/strong> Clone screening of GPR120 clone in HEK inducible stable cell line. The four panels show differences in response across single cell-derived clones in calcium assay via FLIPR. Data is presented as fold over the vehicle.<\/figcaption><\/figure>\n\n\n\nAfter selecting the best clone, this was subsequently characterized using both the selective agonist TUG-891 and the reference antagonist AH7614 to confirm pharmacological responsiveness and receptor-specific activity (Figure 5). The tests were carried out in different independent experiments to determine the assay reproducibility, as well as the consistency in GPR120 expression across passages of the same cell line (Figure 6).<\/p>\n\n\n\nFigure 5<\/strong>. Characterization of GPR120 using a calcium flux assay via FLIPR. Agonist concentration-response curve (top panel) shows a concentration-dependent activation of GPR120 in presence of increasing concentrations of TUG-891. In the bottom panel, a concentration-response curve is displayed for AH 7614 antagonist, showing that increasing concentrations of antagonist block GPR120 activation.<\/figcaption><\/figure>\n\n\n\n
GPR120 exhibits remarkably broad tissue distribution that underlies its pleiotropic physiological roles and expands therapeutic opportunities across multiple disease indications. The highest expression levels are observed in intestinal enteroendocrine L-cells and K-cells (incretin hormone release and appetite regulation), pancreatic islets (enhancement of glucose-stimulated insulin secretion and somatostatin release), adipose tissue (regulation of adipogenesis, lipolysis, thermogenesis, and adipokine secretion), macrophages and microglia (mediation of anti-inflammatory polarization and phagocytic function), central nervous system (energy balance and neurodegeneration) (Figure 1).<\/p>\n\n\n\n This distribution is consistent with the receptor\u2019s emerging role as a regulator of multiple physiological processes, including glucose homeostasis, lipid metabolism, hormone secretion, inflammatory signalling and neurodegeneration.<\/p>\n\n\n\n One reason GPR120 has generated significant scientific interest is its complex signaling biology. Rather than acting within a single metabolic pathway, GPR120 appears to function as part of a wider network that integrates nutritional status with downstream cellular responses. This has made it an attractive target for researchers investigating obesity, type 2 diabetes, and steatotic liver diseases, where dysregulation occurs across multiple interconnected systems.<\/p>\n\n\n\n In humans, two gene products arise upon alternative splicing of exon 3, that can form longer form of GPR120, commonly referred to as FFA4-\u2019Long\u2019 (FFA4-L), as well as a shorter transcript, referred to as FFA4-\u2019Short\u2019 (FFA4-S). FFA4-L contains an additional 16 amino acid sequence within intracellular loop 3 (ICL3), a GPCR domain typically involved in protein interactions, downstream signaling, and desensitization.<\/p>\n\n\n\n The receptor is known to signal through both G\u03b1q\/11<\/sub>-mediated pathways and \u03b2-arrestin 2 recruitment pathways, each contributing to different downstream cellular responses. These pathways influence a range of biological outcomes, including hormone secretion, glucose uptake, cell survival, and inflammatory regulation.<\/p>\n\n\n\n Following identification of different isoforms, it was reported that in response to agonism with the long-chain unsaturated fatty acid oleic acid, native FFA4-L is indeed unable to elicit Ca2+ responses, while FFA4-S produced robust Ca2+ mobilization, suggesting that the short variant of the receptor couples to Ca2+ signaling via G\u03b1q\/11<\/sub>. Both FFA4-L and FFA4-S elicited similar responses toward recruitment of \u03b2-arrestin2, and subsequently, both demonstrate robust internalization and are targeted to lysosomal compartments for degradation. This highlights the signaling differences between the two transcript variants and suggests that the insertion of the 16 amino acids into ICL3 of FFA4-L facilitates intrinsic bias toward \u03b2-arrestin signaling.<\/p>\n\n\n\n Scientists studying GPR120 are therefore faced with an important challenge:<\/p>\n\n\n\n The answer depends on the therapeutic objective. Understanding the biological relevance of each signaling route is essential when selecting assay formats and designing screening strategies, especially for a complex target like GPR120.<\/p>\n\n\n\n In GPCR drug discovery, measuring receptor activation is only part of the challenge. Equally important is ensuring that the chosen assay reflects the biology most relevant to the disease being studied. Poor target validation<\/a> remains a significant contributor to late-stage attrition in drug development. At Sygnature Discovery, we view the whole discovery pipeline as one integrated feedback loop in order to de-risk progression. Therefore, we use our experience and expertise to ensure that target validation is carried out to the highest accuracy using in-house functional assay development<\/a> to study our targets.<\/p>\n\n\n\n For GPR120, the G\u03b1q\/11<\/sub> signaling pathway plays an important role in mediating metabolic effects. As a result, calcium mobilization provides a practical and biologically relevant functional readout for screening programs focused on metabolic applications.<\/p>\n\n\n\n Fluorescence-based calcium flux assays offer several advantages:<\/p>\n\n\n\n As interest in GPR120 grows, robust functional assays will be increasingly important for identifying and characterizing novel agonists, antagonists, and allosteric modulators.<\/p>\n\n\n\n To ensure that screening platforms yield predictive, high-confidence results, target biology must dictate assay design from the ground up. At Sygnature Discovery, building a screening-ready GPR120 platform reflects this philosophy, progressing systematically from construct validation and stable clone selection to rigorous pharmacological characterization.<\/p>\n\n\n\n Indeed, to achieve a reliable screening assay, the full process begins with construct validation via (q)PCR or Western Blot to assess that the target is correctly expressed in cells and it is detectable, followed by the generation and evaluation of stable cell lines capable of delivering strong signal windows, low background activity, and reproducible pharmacological responses.<\/p>\n\n\n\n In Sygnature Discovery\u2019s internally developed GPR120 platform, initial validation was performed using transiently transfected HEK 293 cells, demonstrating functional responses to the selective GPR120 agonist TUG-891(Figure 3).<\/p>\n\n\n\n Stable transfectants were then generated and screened to identify clones capable of supporting robust calcium flux measurements. Several single cell-derived clones expressing GPR120 were evaluated to select those with the strongest assay performance (Figure 4). Once the best clone has been selected, assay optimization and further studies are carried out to pharmacologically characterize the selected clones, and a further stock generation of the selected clones is carried out. This ensures homogeneous receptor expression across stocks and their long-term availability.<\/p>\n\n\n\n After selecting the best clone, this was subsequently characterized using both the selective agonist TUG-891 and the reference antagonist AH7614 to confirm pharmacological responsiveness and receptor-specific activity (Figure 5). The tests were carried out in different independent experiments to determine the assay reproducibility, as well as the consistency in GPR120 expression across passages of the same cell line (Figure 6).<\/p>\n\n\n\nThe Complexity of GPR120 Signaling<\/strong><\/h2>\n\n\n\n
Which signaling pathway should be prioritized when evaluating potential drug candidates?<\/strong><\/h4>\n\n\n\n
Why Functional Assays Matter<\/strong><\/h2>\n\n\n\n
\n
Building a Screening-Ready GPR120 Platform<\/strong><\/h2>\n\n\n\n
![\"Two](\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/11\/Figure-6-Reproducibility-across-experiments.webp\")